{
    "Rank": 158,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01414712",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "STU 032011-212"
                },
                "Organization": {
                    "OrgFullName": "University of Texas Southwestern Medical Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Circulating Tumor Cells in Prostate Cancer Patients",
                "OfficialTitle": "Circulating Tumor Cells in Patients Undergoing Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "March 2013",
                "OverallStatus": "Terminated",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "July 2011"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "December 2011",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "December 2011",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "May 18, 2011",
                "StudyFirstSubmitQCDate": "August 10, 2011",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "August 11, 2011",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "August 19, 2020",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "August 20, 2020",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "University of Texas Southwestern Medical Center",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "The purpose of this study is to determine if a non-invasive cancer treatment, high-dose stereotactic body radiotherapy (SBRT), is associated with changes in circulating tumor cells counts in patients with low- and intermediate-risk prostate cancer.",
                "DetailedDescription": "SBRT (stereotactic body radiotherapy) may decrease or actually increase CTC levels in patients with cancer, and knowledge about the effects of different therapies, including SBRT, on CTC levels will be of general interest to the oncology community. Patients will undergo blood draws at defined times as indicated below.\n\nPrior to CT-simulation, but more than 2 days after digital rectal examination\nWithin 24 hours following CT simulation (an endorectal balloon is used at the time of simulation)\nWithin 24 hours following the first treatment\nWithin 24 hours following the third treatment\nWithin 1 week following the fifth treatment"
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Prostate Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Low- and Intermediate-Risk Prostate Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Case-Only"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Prospective"
                        ]
                    }
                },
                "BioSpec": {
                    "BioSpecRetention": "Samples Without DNA",
                    "BioSpecDescription": "blood"
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "2",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "prostate cancer patients",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Other: Blood Drawing"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Other",
                            "InterventionName": "Blood Drawing",
                            "InterventionDescription": "Blood Drawing to measure circulating tumor cells counts.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "prostate cancer patients"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Blood Drawing for prostate cancer patients who undergo stereotactic body radiotherapy"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "To review the level of changes in circulating tumor cells with radiation.",
                            "PrimaryOutcomeDescription": "The investigator will review the coutns of circulating tumor cells (CTC). If there are significant changes in CTC levels with radiation, future studies will determine the prognostic significance of this information.",
                            "PrimaryOutcomeTimeFrame": "2 weeks"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nMen who satisfy all of the following conditions will be eligible for this study:\n\nWilling and capable to provide informed consent\nSigned study specific informed consent form.\nPSA \u2264 20 prior to hormone therapy (if given) for patients with Gleason 2-6. For those with Gleason score of 7. PSA should be less than or equal to 15 ng/ml prior to hormonal therapy (if given). Thus, risk of pelvic lymph node involvement according to Roach formula would be under 20%.\nGleason score \u2264 7\nAppropriate staging studies identifying as AJCC stage T1a, T1b, T1c, T2a, or T2b\nNo direct evidence of regional or distant metastases after appropriate staging studies\nHistologic confirmation of cancer by biopsy\nAdenocarcinoma of the prostate\nAge \u2265 18\nZubrod Performance Status 0-2\nUp to 9 months of previous hormonal therapy is allowed (but not required)\nAUA score must be \u2264 15 (alpha blockers allowed)\nCT or Ultrasound-based volume estimation of prostate gland \u2264 60 grams\nAgreement to use effective contraceptive methods such as condom/diaphragm and spermicidal foam, intrauterine device, or prescription birth control pills.\n\nExclusion Criteria:\n\nWomen are not eligible for this study. Men with one or more of the following conditions also are ineligible for this study:\n\nPositive lymph nodes or metastatic disease from prostate cancer\nPrior invasive malignancy unless disease free for a minimum of 3 years (carcinoma in situ of the breast, oral cavity, or cervix, or non-melanomatous skin cancer are all permissible)\nT2c, T3, or T4 tumors\nPrevious pelvic radiotherapy\nPrevious surgery or chemotherapy for prostate cancer\nPrevious transuretheral resection of the prostate (TURP) or cryotherapy to the prostate\nPrevious hormonal therapy given for more than 9 months prior to therapy\nConcomitant antineoplastic therapy (including surgery, cryotherapy, conventionally fractionated radiotherapy, and chemotherapy) while on this protocol.\nHistory of Crohn's Disease or Ulcerative Colitis.\nPrevious significant obstructive symptoms; AUA score must be \u2264 15 (alpha blockers allowed)\nSignificant psychiatric illness\nMen of reproductive potential may not participate unless they agree to use an effective contraceptive method.\nUltrasound or CT estimate of prostate volume > 60 grams",
                "HealthyVolunteers": "No",
                "Gender": "Male",
                "MinimumAge": "18 Years",
                "MaximumAge": "99 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Low- and Intermediate-Risk Prostate Cancer wo undergo stereotactic body radiation therapy",
                "SamplingMethod": "Non-Probability Sample"
            },
            "ContactsLocationsModule": {
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "University of Texas Southwestern Medical Center",
                            "LocationCity": "Dallas",
                            "LocationState": "Texas",
                            "LocationZip": "75390",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000011471",
                            "ConditionMeshTerm": "Prostatic Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000009360",
                            "ConditionMeshTerm": "Neoplastic Cells, Circulating"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000005834",
                            "ConditionAncestorTerm": "Genital Neoplasms, Male"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005832",
                            "ConditionAncestorTerm": "Genital Diseases, Male"
                        },
                        {
                            "ConditionAncestorId": "D000091662",
                            "ConditionAncestorTerm": "Genital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000011469",
                            "ConditionAncestorTerm": "Prostatic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000052801",
                            "ConditionAncestorTerm": "Male Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000009362",
                            "ConditionAncestorTerm": "Neoplasm Metastasis"
                        },
                        {
                            "ConditionAncestorId": "D000009385",
                            "ConditionAncestorTerm": "Neoplastic Processes"
                        },
                        {
                            "ConditionAncestorId": "D000010335",
                            "ConditionAncestorTerm": "Pathologic Processes"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M14025",
                            "ConditionBrowseLeafName": "Prostatic Neoplasms",
                            "ConditionBrowseLeafAsFound": "Prostate Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M11995",
                            "ConditionBrowseLeafName": "Neoplastic Cells, Circulating",
                            "ConditionBrowseLeafAsFound": "Circulating Tumor Cells",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M8636",
                            "ConditionBrowseLeafName": "Genital Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2877",
                            "ConditionBrowseLeafName": "Genital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8634",
                            "ConditionBrowseLeafName": "Genital Diseases, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14023",
                            "ConditionBrowseLeafName": "Prostatic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26785",
                            "ConditionBrowseLeafName": "Male Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M11997",
                            "ConditionBrowseLeafName": "Neoplasm Metastasis",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12020",
                            "ConditionBrowseLeafName": "Neoplastic Processes",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            }
        }
    }
}